Evidence map›Paper›PMID 33763618›Full record

ArticleHeliyon2021

Clinical characteristics and risk factors for disease severity and mortality of COVID-19 patients with diabetes mellitus in Kazakhstan: A nationwide study.

Azhar Dyusupova, Raida Faizova, Oksana Yurkovskaya, Tatiana Belyaeva, Tatiana Terekhova, Amina Khismetova, Antonio Sarria-Santamera, Dmitry Bokov, Alexandr Ivankov, Natalya Glushkova

Abstract read
In one paragraph

Article in Heliyon, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Azhar DyusupovaDepartment of Personalized Medicine, Semey Medical University, Semey, Kazakhstan.
Raida FaizovaDepartment of Personalized Medicine, Semey Medical University, Semey, Kazakhstan.
Oksana YurkovskayaDepartment of Personalized Medicine, Semey Medical University, Semey, Kazakhstan.
Tatiana BelyaevaDepartment of Personalized Medicine, Semey Medical University, Semey, Kazakhstan.
Tatiana TerekhovaDepartment of Personalized Medicine, Semey Medical University, Semey, Kazakhstan.
Amina KhismetovaDepartment of Personalized Medicine, Semey Medical University, Semey, Kazakhstan.
Antonio Sarria-SantameraSchool of Medicine, Nazarbayev University, Nur-Sultan, Kazakhstan.
Dmitry BokovInstitute of Pharmacy, Sechenov First Moscow State Medical University, Moscow, Russia.
Alexandr IvankovDepartment of Postgraduate Education, Kazakh Medical University of Continuing Education, Almaty, Kazakhstan.
Natalya GlushkovaDepartment of Epidemiology, Evidence-Based Medicine and Biostatistics, Kazakhstan Medical University Higher School of Public Health, Almaty, Kazakhstan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiabetes mellitus (DM) is associated with higher risk of developing infectious disease and COVID-19 is not the exception. There is a need to generate more data on clinical characteristics and risks of COVID19 patients presenting with DM. In this retrospective study we aimed to report on demographic features, clinical data, and outcomes of COVID-19 patients with DM in comparison with age- and sex-matched patients without DM.

methodsThis was a retrospective study that relied on the nationwide data on all COVID-19 patients who were diagnosed from 14 March to 18 April, 2020. Overall, there were 31 cases with DM for which we randomly matched 4 patients without DM by age and sex.

resultsCOVID-19 patients with associated DM had less beneficial outcomes and more severe disease course both at hospital admission and final diagnosis, as compared with the age and sex-matched non-DM patients. Diabetics were more predisposed to impaired breathing (29.0 % versus 4.9 % in controls), nausea/vomiting (6.5 % versus 0 % in controls) and weakness/lethargy (45.2 % versus 26.0 % in controls). Finally, 48.4 % of diabetics showed the signs of pneumonia on CT scans versus 20.3 % of non-diabetics (p = 0.001), and 32.3 % of DM patients were admitted to intensive care units as compared with just 5.7 % of non-DM patients (p<0.001).

conclusionThere is a need to envisage early status monitoring and supportive care in this vulnerable category of patients to enable better prognosis.

Indexed as

Case-control studyCOVID-19Diabetes mellitusKazakhstanOutcomes

Identifiers

PMID33763618
PMCPMC7972671

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.